Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial

Add time:08/01/2019    Source:sciencedirect.com

BackgroundPatients undergoing general anesthesia for laparoscopic cholecystectomy have a high risk of postoperative nausea and vomiting (PONV) with incidences up to 75%. RAMOSETRON (cas 132036-88-5), a serotonin subtype 3 (5-HT3) antagonist, has been shown to be effective as an antiemetic after chemotherapy and surgery. Consensus guidelines recommend a combination of antiemetic therapies in high-risk groups. Until now, no published data have been available on the use of combination oral plus intravenous ramosetron.

We also recommend Trading Suppliers and Manufacturers of RAMOSETRON (cas 132036-88-5). Pls Click Website Link as below: cas 132036-88-5 suppliers

Prev:RAMOSETRON (cas 132036-88-5) Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women
Next:Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study)